Black Diamond Therapeutics, Inc. (BDTX)
Black Diamond Therapeutics, Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.
Black Diamond Therapeutics, Inc. (BDTX) is a Biotechnology company based in US with a market capitalization of $100.9M. The company generated $29.6M in free cash flow. This page tracks BDTX's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.
US · 24 employees · IPO Jan 31, 2020
Valuation
Valuation & price
$1.76as of Jul 26, 2026· -63.9% vs 52w high
4.5
P/E ratio
Latest-FY diluted EPS
0.90
P/B ratio
Market cap ÷ book equity
No dividend
Dividend yield
Price — last 12 months
Fundamentals
Key fundamentals
$100.9M
Market cap
—
Revenue growth (YoY)
99.5%
Gross margin
$29.6M
Free cash flow (USD)
-$113.6M
Net debt
Net cash position
3.3%
Share dilution
2/5
Graham criteria passed
Defensive-investor screen
Healthcare
Sector
Trajectory
Long-term trends
Revenue by year
2017 → 2025
Free cash flow by year
2017 → 2025
Value screen
Graham defensive-investor tests
0
Insider buys · 90 days
0
Insider sells · 90 days
Earnings
Last report: 10-Q filed May 7, 2026
Next expected: not yet scheduled
On the tape
Recent SEC & insider activity
Questions
Frequently asked questions
What is Black Diamond Therapeutics, Inc.'s market cap?
Black Diamond Therapeutics, Inc. (BDTX) has a market capitalization of $100.9M.
What is BDTX's P/E ratio?
BDTX trades at a price-to-earnings ratio of 4.5, based on its latest fiscal-year diluted earnings per share and the most recent cached price.
What is BDTX's price-to-book (P/B) ratio?
BDTX trades at 0.90 times book value per share.
Does Black Diamond Therapeutics, Inc. pay a dividend?
No — BDTX did not pay a dividend in its latest reported fiscal year.
Are insiders buying BDTX stock?
SEC Form 4 filings show no open-market insider buys at Black Diamond Therapeutics, Inc. in the last 90 days (0 sells).
Same arena
Related companies in Biotechnology
Timeline
Every filing, insider trade & earnings on a price-anchored timeline
Filing Analyzer
Search the actual 10-K / 10-Q text with AI research angles
News
Latest press coverage in one feed
Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.